☆ 4.4 Letter

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors

HEMATOLOGICAL ONCOLOGY (2011)

期刊

HEMATOLOGICAL ONCOLOGY

卷 29, 期 3, 页码 157-160

出版社

WILEY-BLACKWELL

DOI: 10.1002/hon.976

关键词

-

类别

Oncology Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

The Potential Equivalents of TET2 Mutations

Sergiu Pasca, Ancuta Jurj, Mihnea Zdrenghea, Ciprian Tomuleasa

Summary: In acute myeloid leukemia (AML), TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all showing a similar impact on the transcription profile. Other genes also interact with TET2 and influence its effect, potentially leading to the existence of other signatures mimicking TET2 mutations.

CANCERS (2021)

添加到收藏夹

Article Hematology

Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling

Malini Rethnam, Darren Qiancheng Tan, Shi Hao Tan, Jia Li, Rui Yokomori, Ying Li, Henry Yang, Takaomi Sanda, Toshio Suda

Summary: The rare and aggressive hematologic malignancy BPDCN is highly sensitive to PRMT5 inhibition, which not only inhibits cell growth but also mitigates tumor progression. The inhibition of PRMT5 affects the function of key RNA methylation gene METTL3, leading to increased interferon signaling and attenuated sensitivity to PRMT5 inhibition.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Recurrent transcriptional responses in AML and MDS patients treated with decitabine

Pawan Upadhyay, Jeremy Beales, Nakul M. Shah, Agata Gruszczynska, Christopher A. Miller, Allegra A. Petti, Sai Mukund Ramakrishnan, Daniel C. Link, Timothy J. Ley, John S. Welch

Summary: The molecular events responsible for decitabine responses in myelodysplastic syndrome and acute myeloid leukemia patients remain poorly understood. In vivo treatment with decitabine induced global, reversible hypomethylation after 10 days, associated with interferon-induced pathways, expression of endogenous retroviral elements, and inhibition of erythroid-related transcripts. Clinical responses were not correlated with epigenetic or transcriptional signatures, but global hypomethylation by decitabine and reversal of erythroid-related pathways at relapse were observed.

EXPERIMENTAL HEMATOLOGY (2022)

添加到收藏夹

Article Immunology

Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity

Zheng-jun Gao, Wen-ping Li, Xin-tao Mao, Tao Huang, Hao-li Wang, Yi-ning Li, Bao-qin Liu, Jiang-yan Zhong, Chai Renjie, Jin Jin, Yi-yuan Li

Summary: This study reveals that deficiency of Uhrf1 in myeloid cells significantly upregulates Ifnb expression, enhancing resistance to viral infection. Whole-genome bisulfite sequencing identified a single nucleotide methylation site in the Ifnb promoter region that disrupts IRF3 recruitment. Further experiments confirmed the critical role of this methylated site in regulating Ifnb expression and antiviral responses.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹

Review Cell & Tissue Engineering

Clonal hematopoiesis: Mutation-specific adaptation to environmental change

Marcus A. Florez, Brandon T. Tran, Trisha K. Wathan, James DeGregori, Eric M. Pietras, Katherine Y. King

Summary: Clonal hematopoiesis of indeterminate potential (CHIP) refers to the expansion of genetically variant hematopoietic cells, which increases with age and is associated with environmental factors such as infections, chemotherapy, and smoking. Understanding how these environmental contexts alter tissue microenvironments to facilitate the selection and expansion of specific CHIP mutant clones, as well as identifying remaining gaps in knowledge, will have implications for transplant and preventive medicine.

CELL STEM CELL (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Tet2 coordinates with Foxo1 and Runx1 to balance T follicular helper cell and T helper 1 cell differentiation

Andrew Baessler, Camille L. Novis, Zuolian Shen, Jelena Perovanovic, Mark Wadsworth, Kendall A. Thiede, Linda M. Sircy, Malia Harrison-Chau, Nguyen X. Nguyen, Katherine E. Varley, Dean Tantin, J. Scott Hale

Summary: Following viral infection, Tet2-deficient CD4(+) T cells exhibit a preference for differentiating into highly functional germinal center T follicular helper (T-FH) cells. Tet2 coordinates with multiple transcription factors to regulate the demethylation and expression of target genes, including those that inhibit T-FH differentiation.

SCIENCE ADVANCES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Buffering of transcription rate by mRNA half-life is a conserved feature of Rett syndrome models

Deivid C. Rodrigues, Marat Mufteev, Kyoko E. Yuki, Ashrut Narula, Wei Wei, Alina Piekna, Jiajie Liu, Peter Pasceri, Olivia S. Rissland, Michael D. Wilson, James Ellis

Summary: This study measured transcription rate and mRNA half-life changes in RTT patient-derived neurons and reinterpreted nuclear and whole-cell RNAseq from Mecp2 mice. The results showed that dysregulation of genes in RTT is caused by changes in transcription rate or half-life, but genes are buffered when both change. In addition, three dinucleotide frequencies were found to be better predictors of transcription rate changes than CA and CG. MicroRNA and RNA-binding Protein (RBP) motifs were enriched in the 3'UTRs of genes with half-life changes, while nuclear RBP motifs were enriched in buffered genes with increased transcription rate. The study revealed post-transcriptional mechanisms in neurodevelopmental disorders caused by mutations in transcriptional modulator genes.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Oncology

Vitamin C boosts DNA demethylation in TET2 mutation carriers

Aurora Taira, Kimmo Palin, Anna Kuosmanen, Niko Valimaki, Outi Kuittinen, Outi Kuismin, Eevi Kaasinen, Kristiina Rajamaki, Lauri A. Aaltonen

Summary: Recent studies have shown that vitamin C can enhance the demethylation activity of the TET2 gene and reduce DNA hypermethylation. This suggests that vitamin C may play a role in preventing hematological malignancies in individuals with TET2 dysfunction.

CLINICAL EPIGENETICS (2023)

添加到收藏夹

Article Oncology

SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B- cell Lymphomagenesis

Wilfred Leung, Matt Teater, Ceyda Durmaz, Cem Meydan, Alexandra G. Chivu, Amy Chadburn, Edward J. Rice, Ashlesha Muley, Jeannie M. Camarillo, Jaison Arivalagan, Ziyi Li, Christopher R. Flowers, Neil L. Kelleher, Charles G. Danko, Marcin Imielinski, Sandeep S. Dave, Scott A. Armstrong, Christopher E. Mason, Ari M. Melnick

Summary: SETD2 is a histone methyltransferase responsible for H3K36me3 and its mutation can lead to DNA damage and tumor development. Heterozygous deficiency of Setd2 results in germinal center hyperplasia and increased competitive fitness, accelerating lymphomagenesis. SETD2 deficiency impairs DNA damage sensing and repair, leading to increased gene mutations and translocations.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Immunology

Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors

Melanie A. Whitmore, Hong Li, Wentao Lyu, Sharmily Khanam, Guolong Zhang

Summary: The combination of HDACi and DNMTi/HMTi showed a strong synergy in inducing HDP gene expression, and also regulated the expression of tight junction proteins.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Biochemical Research Methods

An improved residual network using deep fusion for identifying RNA 5-methylcytosine sites

Xinjie Li, Shengli Zhang, Hongyan Shi

Summary: This study develops a deep learning model to identify m5C sites in RNA sequences. The model utilizes sequence features extracted from the RNA sequences and incorporates them into an improved residual network for classification. Experimental results show a considerable improvement in accuracy compared to previous studies, demonstrating the robust performance of the model.

BIOINFORMATICS (2022)

添加到收藏夹

Review Oncology

CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors

Sarah C. Reed, Sarah Croessmann, Ben Ho Park

Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is the expansion of leukemia-associated somatic mutations in healthy individuals, which can lead to increased risk of hematologic malignancy, cardiovascular disease, and mortality. Recent research has found high rates of CHIP in patients with solid tumors and suggests a potential role in inflammation and solid tumor biology.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Hematology

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman

Summary: Baseline and sequential molecular profiling by NGS is valuable in identifying patients likely to benefit from HMAs in MDS treatment, particularly in cases with TP53 mutations. TET2 mutation and ASXL1 wild-type genotype are the strongest predictors of treatment response, while TP53 and EZH2 mutations are associated with inferior prognosis.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Cell Biology

Loss of neuronal Tet2 enhances hippocampal-dependent cognitive function

Karishma J. B. Pratt, Jeremy M. Shea, Laura Remesal-Gomez, Gregor Bieri, Lucas K. Smith, Julien Couthouis, Christopher P. Chen, Irena J. Roy, Geraldine Gontier, Saul A. Villeda

Summary: Loss of Tet2 in adult neurons enhances cognitive function, while overexpression of Tet2 impairs memory. Neuronal Tet2 regulates cognitive function by modulating hydroxymethylation of genes involved in synaptic transmission and dendritic complexity.

CELL REPORTS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Codon optimality-mediated mRNA degradation: Linking translational elongation to mRNA stability

Haneui Bae, Jeff Coller

Summary: Translation by the ribosome is the final step in the process of producing proteins from DNA. Recent research has shown that the ribosome also plays a role in controlling mRNA stability and degradation. The rate at which the ribosome moves along the mRNA molecule affects the stability of the transcript. This process is influenced by the codon sequence, with some codons causing the ribosome to pause and adopt a specific conformation that triggers mRNA degradation. These findings suggest that the coding region of mRNA not only determines protein content, but also impacts protein levels by influencing the fate of the transcript.

MOLECULAR CELL (2022)

添加到收藏夹

Review Pathology

Molecular Monitoring of Lymphomas

Joseph G. Schroers-Martin, Stefan Alig, Andrea Garofalo, Benoit Tessoulin, Takeshi Sugio, Ash A. Alizadeh

Summary: Molecular monitoring plays a crucial role in the surveillance and clinical management of lymphomas, aided by the high concentration of cell-free DNA and circulating tumor DNA, high somatic mutational burden, and presence of recurrently altered regions. This review summarizes the current evidence on molecular subtyping, classification, treatment response evaluation, surveillance of cellular therapies, and emerging clinical trial strategies for lymphomas.

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2023)

添加到收藏夹

Article Hematology

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco D'Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, Jose Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Summary: With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. However, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper discusses how established and newly developed molecular testing technologies complement clinical diagnoses and contribute to refining diagnosis, risk stratification, and therapy prediction for lymphoid neoplasms. Future methods such as whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling are likely to become important tools for implementing precision medicine approaches in clinical decision making for lymphoid malignancies.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F. M. Craig, Ulrich Duehrsen, Andreas Huettmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J. Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Andrea Garofalo, Stefan K. Alig, Joseph Schroers-Martin, Ragini Malika Shyam, Mari Olsen, David M. Kurtz, Cedric Rossi, Andre Schultz, Karan R. Kathuria, Chih Long Liu, Valeria Spina, Jamie E. Flerlage, Sharon M. Castellino, Ranjana H. Advani, Davide Rossi, Ryan C. Lynch, Olivier Casasnovas, Lianna J. Marks, Michael P. Link, Marc Andre, Peter Vandenberghe, Christian Steidl, Maximilian Diehn, Ash A. Alizadeh

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin

BLOOD (2022)

添加到收藏夹

Article Oncology

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Brian J. Sworder, David M. Kurtz, Stefan K. Alig, Matthew J. Frank, Navika Shukla, Andrea Garofalo, Charles W. Macaulay, Mohammad Shahrokh Esfahani, Mari N. Olsen, James Hamilton, Hitomi Hosoya, Mark Hamilton, Jay Y. Spiegel, John H. Baird, Takeshi Sugio, Mia Carleton, Alexander F. M. Craig, Sheren F. Younes, Bita Sahaf, Natasha D. Sheybani, Joseph G. Schroers-Martin, Chih Long Liu, Jean S. Oak, Michael C. Jin, Sara Beygi, Andreas Huttmann, Christine Hanoun, Ulrich Duhrsen, Jason R. Westin, Michael S. Khodadoust, Yasodha Natkunam, Robbie G. Majzner, Crystal L. Mackall, Maximilian Diehn, David B. Miklos, Ash A. Alizadeh

Summary: This study investigates the resistance of anti-CD19 chimeric antigen receptor (CAR19) T cells in relapsed/refractory large B-cell lymphoma (r/rLBCL) patients. By analyzing longitudinal samples from two independent cohorts, it identifies multiple gene alterations associated with resistance, such as B cell identity genes (PAX5 and IRF8), immune checkpoint genes (CD274), and genes affecting the tumor microenvironment (TMEM30A). It also reveals that somatic tumor alterations affect CAR19 therapy at various levels, including CAR19 T cell expansion, persistence, and tumor microenvironment. These findings have implications for improving CAR T cells and personalized therapeutic approaches.

CANCER CELL (2023)

添加到收藏夹

Article Oncology

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas

Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kuehn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Rauer, Dieter H. Heiland, Jurgen Finke, Justus Duyster, Julius Wehrle, Marco Prinz, Gerald Illerhaus, Peter C. Reinacher, Elisabeth Schorb, Maximilian Diehn, Ash A. Alizadeh, Florian Scherer

Summary: We explored the value of circulating tumor DNA (ctDNA) for early outcome prediction, measurable residual disease monitoring, and surgery-free CNSL identification. CtDNA was detectable in 78% of pretreatment plasma and 100% of CSF samples. Presence of ctDNA in pretreatment plasma was associated with shorter progression-free survival and overall survival. Monitoring ctDNA during treatment identified patients with poor prognosis. We developed a machine learning approach for biopsy-free CNSL identification from ctDNA.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Hematology

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Ryan C. Lynch, Christina Poh, Chaitra S. Ujjani, Edus H. Warren III, Stephen D. Smith, Mazyar Shadman, Karolyn Morris, Sydney Lee, Heather Rasmussen, Susan Ottemiller, Megan Shelby, Sarith Keo, Kaitlin Verni, David M. Kurtz, Ash A. Alizadeh, Jacob J. Chabon, Gregory J. Hogan, Andre Schulz, Ted Gooley, Jenna M. Voutsinas, Ajay K. Gopal

Summary: The POLARIX trial showed the superiority of Pola over vincristine in the RCHOP regimen for large B-cell lymphomas, but its safety in intensified regimens is unknown. This study evaluated the safety and efficacy of Pola-DA-EPCH-R in aggressive large B-cell lymphomas.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Hua-Jay J. Cherng, Stefan K. Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F. M. Craig, Charles W. Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J. McDonnell, Christopher R. Flowers, Francisco Vega, Michael R. Green, Lei Feng, David M. Kurtz, Ash A. Alizadeh, R. Eric Davis, Jason R. Westin

Summary: LO-CHOP treatment shows high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of overall and complete response. It is a potentially effective and well-tolerated treatment option.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian Till, Vikram M. Raghunathan, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine L. Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ajay K. Gopal

Summary: This study investigated the concurrent administration of pembrolizumab with chemotherapy in untreated classic Hodgkin lymphoma, showing promising safety and efficacy. Although some patients experienced adverse events, the overall response rate was 100% with a complete response rate of 90%.

BLOOD (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment

Kyle Swanson, Eric Wu, Angela Zhang, Ash A. Alizadeh, James Zou

Summary: Machine learning is increasingly used in clinical oncology to diagnose cancers, predict patient outcomes, and inform treatment planning. This review focuses on recent applications of machine learning across the clinical oncology workflow, including medical imaging and molecular data obtained from liquid and solid tumor biopsies for cancer diagnosis, prognosis, and treatment design. Key considerations in developing machine learning for the distinct challenges posed by imaging and molecular data are discussed. The review also examines machine learning models approved for cancer-related patient usage by regulatory agencies and discusses approaches to improve the clinical usefulness of machine learning.

CELL (2023)

添加到收藏夹

Article Oncology

Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

Joseph G. Schroers-Martin, Joanne Soo, Gabriel Brisou, Florian Scherer, David M. Kurtz, Brian J. Sworder, Michael S. Khodadoust, Michael C. Jin, Agnes Bru, Chih Long Liu, Henning Stehr, Paolo Vineis, Yasodha Natkunam, Lauren R. Teras, Joo Y. Song, Bertrand Nadel, Maximilian Diehn, Sandrine Roulland, Ash A. Alizadeh

Summary: Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. CREBBP KAT domain mutations were the most commonly observed precursor lesions, distinguishing patients developing FL from healthy adults with or without BCL2 rearrangements. These mutations can be detected years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development.

CANCER DISCOVERY (2023)

添加到收藏夹

Article Hematology

Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma

Patricia Johansson, Stefan Alig, Julia Richter, Christine Hanoun, Jan Rekowski, Jan Duerig, Bauke Ylstra, Daphne de Jong, Wolfram Klapper, Ash A. Alizadeh, Ulrich Duehrsen, Andreas Huettmann

Summary: In DLBCL, a positive interim PET scan predicts treatment failure, and combining it with the presence of an IgM gammopathy can improve prediction. The combination of interim PET and IgM gammopathy can dichotomize the population into high-risk and low-risk groups with significantly different outcomes. Only the interim PET result and IgM gammopathy status were significantly associated with outcome, making them important factors in risk-adapted treatment strategies.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas

Eliza M. Lauer, Ella Riegler, Jurik A. Mutter, Stefan K. Alig, Sabine Bleul, Julia Kuehn, Lavanya Ranganathan, Christian Klingler, Theo Demerath, Urs Wuertemberger, Alexander Rau, Jakob Weiss, Michel Eisenblaetter, Fabian Bamberg, Marco Prinz, Juergen Finke, Justus Duyster, Gerald Illerhaus, Maximilian Diehn, Ash A. Alizadeh, Elisabeth Schorb, Peter C. Reinacher, Florian Scherer

Summary: The study found that the use of semi-automated three-dimensional tumor volume measurements can serve as strong and independent early predictors of clinical outcomes in central nervous system lymphoma (CNSL) patients. These radiologic features can help improve risk stratification and guide future treatment approaches.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Letter Medicine, General & Internal

Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin

Adam C. Palmer, David M. Kurtz, Ash A. Alizadeh

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.